Skip to evidence report

ASPC.adipocyte_capillary_interface: Studies — page 13

How association tiers are defined — cell–trait and gene–trait

SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.

Cell–trait tiers

Cell–trait links
Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
Required for Specific or Relevant
The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
Specific (Tier 1)
Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
Relevant (Tier 2)
Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
Interpretation and report values
CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
Meta traits and individual traits
Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.

Gene–trait priorities (variant–tCRE–gene evidence)

Variant–tCRE–gene links
Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
Required genetic support
The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
Required cellular support
The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
High priority
Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
Medium priority
Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
Same-record evidence and aggregation
Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
Limits of interpretation
A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.

State · 1,040 full-atlas cells · all tissues.

Marker genes and cell annotation · Open this population in Cell Browser →

ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.

Rows 12,001–12,313 of 12,313; ranked by score descending. Equal values use name/identifier order.

Studies ranked for ASPC.adipocyte_capillary_interface
#Trait / studyIndividual trait IDMean IC score
12001eosinophil (fraction, minimum, inv-norm transformed)GCST904753032.58e-03
12002CSF3 levelsGCST904688862.57e-03
12003DRAXIN levelsGCST904690382.57e-03
12004MAVS/TBL1X ratioGCST903153992.57e-03
12005CST5 levelsGCST904688952.56e-03
12006Educational attainment (confirmatory factor analysis Factor 10)GCST903093442.56e-03
12007LAMP3/PRSS8 ratioGCST903152752.55e-03
12008SUSD4 levelsGCST904707882.51e-03
12009Psoriasis vulgaris (PheCode 696.41)GCST904761902.49e-03
12010IL5RA levelsGCST904696002.48e-03
120111-stearoylglycerophosphoethanolamine levelsGCST902437802.47e-03
12012SPINT1/SUSD2 ratioGCST903158782.46e-03
12013Chronic lower respiratory diseasesFING000002902.45e-03
12014DTI autoptx MD fmi tractGCST903852312.45e-03
12015EBAG9/EDAR ratioGCST903145632.45e-03
12016Essential tremor (PheCode 333.1)GCST904758322.45e-03
12017Phosphatidylcholine-O_40:5_[M+H]1+/Phosphatidylcholine-P_40:4_[M+H]1+ levelsGCST900604232.44e-03
12018Blood cell traits latent factor 22 (white cell)GCST905592642.44e-03
12019AMY1A or AMY1B or AMY1C levelsGCST904682972.43e-03
12020HLAE/IL15 ratioGCST903150612.43e-03
12021Blood cell traits latent factor 17 (white cell)GCST905592592.43e-03
12022Occupational attainmentGCST901022532.40e-03
12023DBNL/VASH1 ratioGCST903144272.39e-03
12024F2R/TNFRSF14 ratioGCST903147392.39e-03
12025CRELD2/HYOU1 ratioGCST903142552.39e-03
12026Malignant neoplasm of kidney, except pelvis (PheCode 189.11)GCST904755972.39e-03
12027CD48/SLAMF7 ratioGCST903138422.39e-03
12028GP1BA/SELP ratioGCST903149582.38e-03
12029Acute bronchitisFING000000212.37e-03
12030Attention deficit hyperactivity disorderGCST905684412.36e-03
12031FLT3LG levelsGCST904692502.33e-03
12032DiabetesGCST904681242.32e-03
12033Clonal hematopoiesis (DNMT3A mutation)GCST904353542.32e-03
12034ACY1/DCXR ratioGCST903131622.31e-03
12035TNFRSF13B/TNFRSF13C ratioGCST903159312.31e-03
12036KLKB1 levelsGCST904697082.31e-03
12037Functional dyspepsiaFING000005612.30e-03
12038CES2 levelsGCST904687192.30e-03
12039Sacroiliitis, not elsewhere classifiedFING000012732.29e-03
12040TNFRSF13B/TNFSF13B ratioGCST903159332.28e-03
12041Psoriasis (PheCode 696.4)GCST904761872.27e-03
12042EDAR/YES1 ratioGCST903145942.26e-03
12043CLEC4G/KEL ratioGCST903141192.25e-03
12044DTI autoptx MD ifo r tractGCST903852332.25e-03
12045Subclinical hypothyroidism in pregnancyGCST904351972.22e-03
12046Omega-6 fatty acid levelsGCST905025182.21e-03
12047Thyrotoxicosis with diffuse goitreFING000013612.20e-03
12048Primary biliary cholangitisGCST900614402.20e-03
12049FCRL1 levelsGCST904692052.20e-03
12050Other specified disorders of external earFING000011042.20e-03
12051APRT/EREG ratioGCST903133352.19e-03
12052CRELD2/NUCB2 ratioGCST903142562.19e-03
12053Malignant melanoma, excluding all cancers (controls excluding all cancers)FING000007502.17e-03
12054Operation code - cholecystectomy/gall bladder removal | OperationsUKBB000005542.15e-03
12055Diabetes diagnosed by doctor | Medical conditionsUKBB000001682.13e-03
12056Psoriasis and related disorder (PheCode 696)GCST904761862.13e-03
12057Basophil countGCST900187262.12e-03
12058Mean spheric corpuscular volumeGCST900023972.11e-03
12059GP1BA/HBEGF ratioGCST903149562.11e-03
12060CD40LG/EDAR ratioGCST903138182.10e-03
12061Other acute lower respiratory infectionsFING000009212.10e-03
12062Asthma (more control exclusions)FING000001132.09e-03
12063Platelet crit (UKB data field 30090)GCST904680962.09e-03
12064REG1B/REG3A ratioGCST903157652.08e-03
12065Mean corpuscular volumeGCST900023922.08e-03
12066EDAR/PRDX5 ratioGCST903145832.08e-03
12067REST UKBBICA NODEamps25 0001GCST903854842.07e-03
12068Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T464ECGA0004642.07e-03
12069Rheumatoid arthritisGCST901322232.07e-03
12070LYN/SIRT2 ratioGCST903153492.06e-03
12071Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T462ECGU0004622.06e-03
12072MYL3 levelsGCST904699772.04e-03
12073DSC2 levelsGCST904690402.04e-03
12074CNST/DOK2 ratioGCST903141572.03e-03
12075CD163/FOLR2 ratioGCST903137342.01e-03
12076CLSTN3 levelsGCST904687902.01e-03
12077Oral glucose tolerance test-1hGCST905664222.00e-03
12078KDM3A levelsGCST904696712.00e-03
12079NID1/SORT1 ratioGCST903155422.00e-03
12080OSCAR levelsGCST904701311.99e-03
12081TNFRSF11A levelsGCST904709021.96e-03
12082Disorders of the thyroid glandFING000004631.95e-03
12083ERBB4/UMOD ratioGCST903146921.94e-03
12084Omega-3 fatty acids to Omega-6 fatty acids ratioGCST905020681.94e-03
12085Clonal hematopoiesis (overall)GCST904353531.93e-03
12086SEPTIN3 levelsGCST904705761.93e-03
12087Atopic/contact dermatitis due to other or unspecified (PheCode 939)GCST904762891.92e-03
12088FCRL5/ICAM3 ratioGCST903148021.92e-03
12089Mean reticulocyte volumeGCST900023961.90e-03
12090F2R/SEMA4D ratioGCST903147341.90e-03
12091Glycated haemoglobin (HbA1c) | Blood biochemistryUKBB000002891.89e-03
12092Free thyroxine levels within normal range in pregnancyGCST904351961.89e-03
12093APBB1IP/NADK ratioGCST903132981.88e-03
12094Omega-3 fatty acids to total fatty acids percentageGCST905020871.87e-03
12095CD58/SIRPB1 ratioGCST903138551.87e-03
12096Repeated disturbing thoughts of stressful experience in past month | Traumatic eventsUKBB000007501.87e-03
12097Thyroid problemsGCST904752761.86e-03
12098SpondyloarthritisFING000013231.86e-03
12099GGH levelsGCST904693351.85e-03
12100OSM levelsGCST904701331.84e-03
12101Migraine headachesGCST904755461.82e-03
12102White blood cell count (basophil)GCST0046181.82e-03
12103Other noninfective gastroenteritis and colitisFING000010771.81e-03
12104Neutrophil countGCST900187481.81e-03
12105BLNK levelsGCST904684481.81e-03
12106Handedness (chirality/laterality) - Left-handed | Early life factorsUKBB000003021.80e-03
12107HypothyroidismGCST902041671.80e-03
12108Mean reticulocyte volume | Blood countUKBB000004511.78e-03
12109Platelet crit | Blood countUKBB000006471.78e-03
12110CA14 levelsGCST904685091.77e-03
12111CRISP3 levelsGCST904688661.77e-03
12112Cancer code, self-reported - basal cell carcinoma | Medical conditionsUKBB000001171.76e-03
12113Taking other prescription medications | MedicationUKBB000008131.76e-03
12114Asthma-related pneumoniaFING000001191.76e-03
12115CD5/CD6 ratioGCST903138601.76e-03
12116MAMDC4 levelsGCST904698421.76e-03
12117eosinophil (absolute count, minimum, inv-norm transformed)GCST904752941.76e-03
12118SIGLEC8 levelsGCST904706361.75e-03
12119Right-hemisphere control network to accumbens white-matter structural connectivityGCST903028421.75e-03
12120CCN2/HBEGF ratioGCST903137131.74e-03
12121Self-rated healthGCST0066201.74e-03
12122DLL1/NBL1 ratioGCST903144961.72e-03
12123CD244/TREML2 ratioGCST903137671.72e-03
12124Mean reticulocyte volumeGCST900259751.72e-03
12125MCTS1 levelsGCST904698741.70e-03
12126Avoided activities or situations because of previous stressful experience in past month | Traumatic eventsUKBB000000831.68e-03
12127Plasma argininate* levels in chronic kidney diseaseGCST902648261.65e-03
12128DAB2/ERBIN ratioGCST903143611.65e-03
12129APBB1IP levelsGCST904683271.64e-03
12130BSG/LY9 ratioGCST903135341.64e-03
12131IL2RA levelsGCST904695851.63e-03
12132PIGR levelsGCST904702321.63e-03
12133MelanomaGCST900118091.62e-03
12134CCL5/SELP ratioGCST903137051.62e-03
12135Treatment or medication use - levothyroxine sodium (UKB data field 20003_1141191044)GCST900425351.62e-03
12136PRTN3 levelsGCST904703481.61e-03
12137EDAR/ENO2 ratioGCST903145741.61e-03
12138WeightGCST902786501.61e-03
12139mean corpuscular volume (MCV, maximum, inv-norm transformed)GCST904754661.61e-03
12140CXCL11 levelsGCST904689241.60e-03
12141TNFRSF10B levelsGCST904709001.60e-03
12142neutrophil (fraction, maximum, inv-norm transformed)GCST904755351.60e-03
12143Psoriatic arthritisGCST902439561.59e-03
12144REG1A/REG3A ratioGCST903157611.59e-03
12145HNRNPK/VASH1 ratioGCST903150711.59e-03
12146mean corpuscular volume (MCV, minimum, inv-norm transformed)GCST904754741.57e-03
12147Patient classification on admission (recoded) - Inpatient | Summary AdministrationUKBB000006371.57e-03
12148GOLM2 levelsGCST904693761.54e-03
12149Basophil percentage of white cellsGCST0046311.53e-03
12150DBNL/EDAR ratioGCST903144161.52e-03
12151CD69/CHMP1A ratioGCST903138681.52e-03
12152CD5L levelsGCST904686401.52e-03
12153ICAM3/TNFRSF13B ratioGCST903151241.50e-03
12154Uterine fibroidsGCST904681541.50e-03
12155Rheumatoid arthritisGCST900186901.46e-03
12156CRTAM levelsGCST904688711.46e-03
12157DAG1/HBEGF ratioGCST903143761.45e-03
12158BAG6/BMP6 ratioGCST903134501.45e-03
12159DEFA1 or DEFA1B levelsGCST904689791.45e-03
12160F-meat liking (derived food-liking factor)GCST900947991.43e-03
12161Mean reticulocyte volume (UKB data field 30260)GCST904680881.42e-03
12162CD48/CRTAM ratioGCST903138391.42e-03
12163mean corpuscular volume (MCV, mean, inv-norm transformed)GCST904754701.42e-03
12164Alcohol intake versus 10 years previously | AlcoholUKBB000000241.41e-03
12165LPO levelsGCST904697891.39e-03
12166ERBB2/GUSB ratioGCST903146871.37e-03
12167Omega-3 fatty acids to total fatty acids percentageGCST905024601.37e-03
12168F2R levelsGCST904691681.37e-03
12169METAP2/RILP ratioGCST903154331.36e-03
12170CRISP2 levelsGCST904688651.33e-03
12171IFNLR1 levelsGCST904695181.33e-03
12172Interpolated Age of participant when non-cancer illness first diagnosed | Medical conditionsUKBB000003691.33e-03
12173CTSB levelsGCST904689081.32e-03
12174LAYN/ULBP2 ratioGCST903152921.30e-03
12175CXCL5/EDAR ratioGCST903143491.29e-03
12176Red wine consumption (glasses per month) (UKB data field 1578, 4419)GCST901329871.29e-03
12177Cheese intake | DietUKBB000001271.29e-03
12178Mean corpuscular volumeGCST0046021.28e-03
12179KEL levelsGCST904696731.27e-03
12180HBEGF/PDGFB ratioGCST903150341.27e-03
12181Alanine levelsGCST904970851.26e-03
12182MYLPF levelsGCST904699801.25e-03
12183Treatment/medication code - metformin | MedicationsUKBB000008511.25e-03
12184FGF2/HBEGF ratioGCST903148111.25e-03
12185GHRL levelsGCST904693411.25e-03
12186Overweight, obesity and other hyperalimentation | endocrine/metabolicUKBB000006221.25e-03
12187LY9 levelsGCST904698241.24e-03
12188Hypothyroidism, strict autoimmuneFING000006561.23e-03
12189CRTAM/VCAM1 ratioGCST903142811.23e-03
12190Clonal haematopoiesis of indeterminate potential (with or without mosaic chromosomal alteration)GCST901652671.22e-03
12191Red blood cell countGCST902786411.21e-03
12192Mean corpuscular volume (UKB data field 30040)GCST904680861.21e-03
12193Disorders of bilirubin excretion (PheCode 277.4)GCST904757561.21e-03
12194TNFRSF13C/TNFSF13B ratioGCST903159341.19e-03
12195NADK/PXN ratioGCST903155121.17e-03
12196TNFRSF6B levelsGCST904709141.16e-03
12197Mosaic chromosomal alteration of the Y chromosomeGCST901652891.15e-03
12198mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed)GCST904754421.15e-03
12199mean corpuscular hemoglobin (MCH, minimum, inv-norm transformed)GCST904754501.14e-03
12200ADGRE5/SEMA7A ratioGCST903131831.14e-03
12201Coeliac diseaseFING000003121.14e-03
12202IL5RA/TNFRSF13B ratioGCST903151641.13e-03
12203Cheese consumptionGCST901330001.13e-03
12204PRG3 levelsGCST904703231.13e-03
12205Blood cell traits latent factor 18 (platelet)GCST905592601.12e-03
12206PDCD1 levelsGCST904701811.11e-03
12207Oral glucose tolerance test-0hGCST905664211.11e-03
12208IDP T1 SIENAX peripheral grey unnormalised volumeGCST900024271.08e-03
12209EDAR/F11R ratioGCST903145761.07e-03
12210Late-onset myasthenia gravisGCST900934661.07e-03
12211CD244/CRTAM ratioGCST903137631.06e-03
12212ST6GAL1 levelsGCST904707531.05e-03
12213DAG1/F2R ratioGCST903143741.04e-03
12214HypothyroidismGCST904681381.04e-03
12215FASLG levelsGCST904691911.03e-03
12216Red blood cell countGCST900023641.03e-03
12217ICAM3/SLAMF7 ratioGCST903151231.03e-03
12218Mean corpuscular hemoglobinGCST900023901.03e-03
12219mean corpuscular hemoglobin (MCH, mean, inv-norm transformed)GCST904754461.02e-03
12220Obesity | endocrine/metabolicUKBB000005441.01e-03
12221DAPP1/ITGB1BP2 ratioGCST903143889.89e-04
12222Squamous cell neoplasms and carcinomas of the skin, excluding all cancers (controls excluding all cancers)FING000013309.87e-04
12223ARHGAP30 levelsGCST904683549.80e-04
12224Primary sclerosing cholangitisGCST0040309.74e-04
12225GALNT5 levelsGCST904692989.73e-04
12226Obesity | Obesity and other hyperalimentationUKBB000005459.53e-04
12227Glucose levelsGCST900928199.53e-04
12228FAM3B/FUT3_FUT5 ratioGCST903147779.35e-04
12229CKAP4/TNFRSF4 ratioGCST903140769.23e-04
12230CXCL5/PLXNA4 ratioGCST903143519.16e-04
12231RNASET2 levelsGCST904704819.09e-04
12232Follicular lymphoma, hilmo (controls excluding all cancers)FING000005489.05e-04
12233Ankylosing spondylitisFING000000898.98e-04
12234CD244 levelsGCST904686118.94e-04
12235ThyrotoxicosisFING000013608.89e-04
12236CD6/EZR ratioGCST903138908.85e-04
12237EDAR/SERPINB1 ratioGCST903145868.57e-04
12238Mean corpuscular volumeGCST900023358.36e-04
12239CCL19 levelsGCST904685718.28e-04
12240EPHB6/VWC2 ratioGCST903146838.16e-04
12241GDF15 levelsGCST904693218.01e-04
12242Red blood cell countGCST900187517.92e-04
12243TPSAB1 levelsGCST904709517.68e-04
12244GZMA levelsGCST904694237.66e-04
12245SLAMF7 levelsGCST904706517.66e-04
12246T1 CAT WM unnormalised volumeGCST903839837.59e-04
12247APP/HBEGF ratioGCST903133247.54e-04
12248HBEGF/SDC4 ratioGCST903150377.49e-04
12249NFATC1/SPRY2 ratioGCST903155397.47e-04
12250CXCL11/SDC4 ratioGCST903143367.41e-04
12251Mean corpuscular volume | Blood countUKBB000004497.30e-04
12252VSTM1 levelsGCST904710557.29e-04
12253CXCL11/DKK1 ratioGCST903143347.26e-04
12254TNF levelsGCST904709247.20e-04
12255Mean corpuscular haemoglobin | Blood countUKBB000004477.01e-04
12256EZR levelsGCST904691627.00e-04
12257EFNA4 levelsGCST904690816.95e-04
12258Physical activityGCST900933246.93e-04
12259Mean corpuscular haemoglobin (UKB data field 30050)GCST904680846.82e-04
12260Myasthenia gravisGCST900930616.77e-04
12261IL16 levelsGCST904695576.70e-04
12262FCAR levelsGCST904691976.63e-04
12263HypothyroidismGCST903193206.62e-04
12264CLEC1A levelsGCST904687676.44e-04
12265CD6 levelsGCST904686446.32e-04
12266All pneumoniaeFING000000656.30e-04
12267Mean corpuscular volumeGCST900187466.27e-04
12268Hypothyroidism (PheCode 244)GCST904756476.22e-04
12269MMP8/OLR1 ratioGCST903154646.12e-04
12270Mean corpuscular hemoglobinGCST900023236.02e-04
12271red blood cell count (RBC, mean, inv-norm transformed)GCST904763495.98e-04
12272Non-cancer illness code, self-reported - diabetes | Medical conditionsUKBB000005085.93e-04
12273KLRD1 levelsGCST904697115.71e-04
12274CD72 levelsGCST904686465.70e-04
12275IL16/NADK ratioGCST903151525.69e-04
12276Takes medication for Thyroid problems?GCST904752775.59e-04
12277CC2D1A/STAMBP ratioGCST903136645.58e-04
12278TNFRSF13C levelsGCST904709065.53e-04
12279Red blood cell (erythrocyte) count | Blood countUKBB000007475.24e-04
12280IL1RN levelsGCST904695765.12e-04
12281Mean corpuscular hemoglobinGCST0046305.02e-04
12282Hypothyroidism NOS (PheCode 244.4)GCST904756534.77e-04
12283CFHR4 levelsGCST904687274.46e-04
12284ADA2 levelsGCST904682154.39e-04
12285T1 CAT GM unnormalised volumeGCST903839824.28e-04
12286COPD/asthma/ILD related infectionsFING000003534.19e-04
12287ICAM3 levelsGCST904695004.13e-04
12288Telomere length (principal component 1)GCST904351444.06e-04
12289CD48 levelsGCST904686353.82e-04
12290VMO1 levelsGCST904710423.81e-04
12291GCNT1 levelsGCST904693193.72e-04
12292Oral glucose tolerance test-0hGCST902977883.36e-04
12293Red blood cell countGCST900024033.27e-04
12294Influenza and pneumoniaFING000006792.95e-04
12295Red blood cell erythrocyte count (UKB data field 30010)GCST904680982.94e-04
12296APBB1IP/POLR2F ratioGCST903133002.92e-04
12297PRG2 levelsGCST904703222.70e-04
12298MANSC1/PODXL2 ratioGCST903153712.62e-04
12299CLEC4G levelsGCST904687742.56e-04
12300CLEC4C levelsGCST904687722.52e-04
12301ADAM8 levelsGCST904682202.39e-04
12302Mean corpuscular hemoglobinGCST900187442.24e-04
12303Takes medication for skin cancer?GCST904751902.23e-04
12304TG levelsGCST904708512.06e-04
12305CLEC7A levelsGCST904687782.06e-04
12306Red blood cell countGCST0046012.01e-04
12307IDP T1 SIENAX grey unnormalised volumeGCST900024311.91e-04
12308Breast cancer (triple negative or BRCA1-positive)GCST0101001.64e-04
12309S100P levelsGCST904705209.18e-05
12310Mineral and other dietary supplements - Calcium | MedicationUKBB000004718.68e-05
12311red blood cell count (RBC, maximum, inv-norm transformed)GCST904763455.82e-05
12312red blood cell count (RBC, minimum, inv-norm transformed)GCST904763533.05e-05
12313CEBPB/NADK ratioGCST903140062.32e-05